
Adalimumab
CAS No. 331731-18-1
Adalimumab( —— )
Catalog No. M22133 CAS No. 331731-18-1
Adalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 404 | In Stock |
![]() ![]() |
10MG | 642 | In Stock |
![]() ![]() |
25MG | 999 | In Stock |
![]() ![]() |
50MG | 1341 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAdalimumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAdalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
-
DescriptionAdalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number331731-18-1
-
Formula Weight148 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mease PJ, et al. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2005 Nov;5(11):1491-504.
molnova catalog



related products
-
CDC801
CDC801 is a potent and orally active inhibitor of PDE4 and TNF-α (IC50: 1.1 μM and 2.5 μM).
-
Clematichinenoside A...
Clematichinenoside AR exerts anti-inflammatory and immunosuppressive properties, it has anti-arthritic effects on PI3K/Akt signaling pathway and TNF-α± associated with collagen-induced arthritis.
-
Physcion 8-O-β-D-glu...
Physcion 8-O-β-D-glucopyranoside has anti-inflammatory and anti-cancer activities. Physcion 8-O-β-D-glucopyranoside can be used in studies about common malignancy cancer.